Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the Europ

Date publication

juillet 2016

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DAGUINDAU Etienne

Tous les auteurs :
Styczynski J, Tridello G, Gil L, Ljungman P, Hoek J, Iacobelli S, Ward KN, Cordonnier C, Einsele H, Socie G, Milpied N, Veelken H, Chevallier P, Yakoub-Agha I, Maertens J, Blaise D, Cornelissen J, Michallet M, Daguindau E, Petersen E, Passweg J, Greinix H, Duarte RF, Kröger N, Dreger P, Mohty M, Nagler A, Cesaro S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27091716

Résumé

We investigated the effect of Epstein-Barr virus (EBV) serostatus on the overall outcome of allogeneic hematopoietic stem-cell transplantation (allo-HSCT).

Mots clés

Adolescent, Adult, Aged, Antibodies, Viral, blood, Child, Child, Preschool, Female, Graft vs Host Disease, epidemiology, Hematopoietic Stem Cell Transplantation, adverse effects, Herpesvirus 4, Human, isolation & purification, Humans, Incidence, Infant, Leukemia, Myeloid, Acute, therapy, Male, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, therapy, Tissue Donors

Référence

J. Clin. Oncol.. 2016 07 1;34(19):2212-20